Digital Health Weekly - 02 - 06 Mar, 2026

• CSIRO's ON Accelerate program has selected a new cohort of research‑driven ventures, highlighting two AI‑based health solutions: DermAI for point‑of‑care skin‑cancer detection and PredicTx Health for AI‑personalised chemotherapy dosing. 
• DermAI, a handheld imaging platform from the University of Melbourne, enables doctors to quickly assess skin‑cancer risk at the bedside, improving early detection for rural and underserved Australians where 2 in 3 people develop skin cancer by age 70. 
• PredicTx Health uses routine imaging, genomics and clinical data to tailor chemotherapy doses to individual patients, aiming to reduce toxicity, improve safety and bring precision oncology into routine practice. 
• CareWindow, a spin‑out from Flinders University, offers a zero‑touch digital care platform that lets families monitor wellbeing of older adults without requiring fine motor skills or digital literacy, expanding accessible healthcare. 

• Seven Victorian startups, including 4D Medical, Arelis, Lenexa Medical, Mediklean, MX3 Diagnostics, Proton Intelligence Australia, and Sadleir Laboratories, were selected for MTPConnect’s Pathway to Market – Medtech Capability Uplift Program. 
• The not‑for‑profit accelerator announced the 2026 cohort at an event held at the Victorian Heart Hospital on Wednesday. 
• The program will support development of solutions such as 4D lung imaging and AI‑enabled bedsore prevention, and may expand to other Australian states. 
• Participation aims to accelerate medtech commercialization and strengthen the regional digital health ecosystem. 

• An Australian-made AI tool, trained on millions of mammograms from Australian women, can estimate a woman's risk of developing breast cancer more accurately than current methods such as age and family history. 
• The AI tool, called BRAIx, provides a personalized risk score from 0 to 99.9 that predicts a woman's likelihood of developing breast cancer over the next four years, identifying high‑risk women missed by standard screening. 
• Published in Lancet Digital Health, the study showed that one in ten women in the top 2 % of BRAIx scores developed cancer despite clear mammograms, outperforming traditional risk models based on age, family history and breast density. 
• Researchers aim to roll out the tool within five years, expecting it to support radiology staffing shortages, lower system costs, and move toward the goal of zero breast‑cancer deaths in Australia. 

• OpenAI launched ChatGPT Health in January 2026, enabling U.S. users to connect medical records and reaching roughly 40 million adults each day. 
• A safety study in Nature Medicine (23 February) found the tool under‑triaged 52 % of gold‑standard emergencies, directing patients with diabetic ketoacidosis or impending respiratory failure to 24‑48 hour evaluation instead of the emergency department. 
• The study also revealed frequent failures to detect suicidal ideation, with crisis‑line alerts often triggered in low‑risk scenarios and absent when users described specific self‑harm plans. 
• Over‑reaction was noted in low‑risk cases, as 64.8 % of safe individuals were incorrectly advised to seek immediate medical care, underscoring the need for critical user assessment of AI health advice. 

• Xsensio has closed a USD 7 million oversubscribed Series A financing round, led by WI Harper, to accelerate clinical deployment of its Lab‑on‑Skin wearable biosensing platform. 
• The Lab‑on‑Skin platform, developed at EPFL Innovation Park, integrates multiple sensors onto an ultra‑miniaturized chip to continuously monitor biomarkers (metabolites, ions, proteins, hormones) via interstitial fluid on the skin, with a modular architecture for diverse clinical uses. 
• Xsensio announced a long‑term collaboration with Texas Instruments to enable CMOS integration, further miniaturization, and large‑scale manufacturability of the platform. 
• The new funding builds on Xsensio’s 2023 partnership with Mayo Clinic for clinical validation of critical‑care monitoring in hospital and home settings.

• Temple secured $54 million in a friends‑and‑family round for his wearable startup Temple, valuing the company at about $190 million. 
• Temple is developing a temple‑mounted sensor that continuously tracks brain blood flow, aiming to measure performance metrics unavailable in current wearables for elite athletes. 
• The company announced a broad hiring push for expertise in embedded systems, neuroscience, and brain‑computer‑interface engineering, with over 30 employees joining at the same valuation. 
• This funding aligns with Goyal’s “high‑risk, high‑reward” strategy, complementing his $25 million personal investment in longevity research and previous health‑tech backing such as Ultrahuman.

• Oura acquired Doublepoint, a Finnish startup specializing in AI-driven gesture recognition, enabling devices to be controlled through subtle hand movements.
• The technology will help Oura develop future products where users interact with wearables through natural gestures and voice, creating more intuitive and “ambient” computing experiences.
• Oura will integrate Doublepoint’s AI engineers and four founders, who will help design next-generation interaction features for Oura’s ecosystem.
• This is Oura’s fourth acquisition, supporting its expansion from a health-tracking ring into a broader wearable AI platform and strengthening its innovation roadmap.

• Qualcomm has unveiled a new chip, Snapdragon Wear Elite, designed for wearable devices like smart glasses, pendants, and badges that can operate without a screen and potentially record users' surroundings. 
• The chip is intended to run AI models and interact with nearby devices without needing to swap batteries, and will power devices from companies like Google, Motorola, and Samsung. 
• Tech giants are exploring the potential for AI‑powered wearable gadgets to perform tasks more efficiently than smartphones, such as real‑time translations and context‑aware responses, but must address privacy concerns and prove their value to consumers. 
• The development of these devices raises concerns about covert recording and the need for companies to balance convenience with respect for users' privacy, with some devices already incorporating LED indicators to signal when recording is taking place.